Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
NYSE
00:00:02 15/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 86.45 USD | +1.38% |
|
+0.78% | +1.41% |
| 03:50pm | Baird Adjusts Price Target on Edwards Lifesciences to $90 From $94 | MT |
| 10-05 | Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 49,830 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | 0.73% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 46,199 | 44,635 | 42,819 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 0.78% | -3.38% | -4.07% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 34.8x | 26x | 23.2x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.7x | 4.09x | 3.79x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 1x | 0.8x | 1.9x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.37x | 6.7x | 6.09x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 6.83x | 6x | 5.23x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 21.7x | 18.8x | 16x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 23.5x | 20.2x | 17.3x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 54.4x | 27.7x | 23.6x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 1.84% | 3.61% | 4.25% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.486 | 3.322 | 3.733 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,763 | 7,433 | 8,185 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,131 | 2,378 | 2,680 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,970 | 2,212 | 2,481 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,435 | 1,898 | 2,040 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,631 | -5,195 | -7,011 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 86.45 | 86.45 | 86.45 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 576,400 | - | - |
| Announcement Date | 26/01/22 | 31/01/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.77x | 6.83x | 21.68x | -.--% | 49.83B | ||
| 33.45x | 5.86x | 22.43x | 0.28% | 249B | ||
| 38.23x | 6.77x | 21.45x | 0.63% | 158B | ||
| 44.89x | 12.07x | 26.63x | -.--% | 148B | ||
| 16.16x | 3.25x | 10.59x | -.--% | 62.32B | ||
| 19.71x | 2.38x | 12.06x | 2.55% | 49.61B | ||
| 45.53x | 11.13x | 24.54x | -.--% | 48.14B | ||
| 33.9x | 6.7x | 22.76x | 0.59% | 49.06B | ||
| 76.44x | 7.29x | 22.2x | -.--% | 42.9B | ||
| 54.94x | 8.87x | 31.53x | -.--% | 41.04B | ||
| Average | 39.80x | 7.11x | 21.59x | 0.41% | 89.82B | |
| Weighted average by Cap. | 38.00x | 7.26x | 22.05x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
















